Scilex Holding (SCLXW) Total Liabilities (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Total Liabilities of $547.7 million in Q1 2026, down 5.03% quarter-over-quarter from $576.7 million in Q4 2025, and up 88.56% on a YoY basis from $290.5 million in Q1 2025.
Scilex Holding (SCLXW) Total Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Liabilities history runs 7 years deep, the most recent figure standing at $547.7 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 88.56% year-over-year to $547.7 million; the TTM figure through Mar 2026 stood at $547.7 million (up 88.56% YoY), while the FY2025 annual figure was $576.7 million, up 101.94% from the prior year.
- Total Liabilities was $547.7 million for Q1 2026 at Scilex Holding, down from $576.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $576.7 million in Q4 2025 to a low of $11.1 million in Q1 2022.
- Historically, Total Liabilities has averaged $249.2 million across 5 years, with a median of $281.0 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 83.34% in 2022, then soared 1898.54% in 2023.
- A 5-year view of Total Liabilities shows it stood at $50.3 million in 2022, then soared by 445.35% to $274.2 million in 2023, then gained by 4.14% to $285.6 million in 2024, then soared by 101.94% to $576.7 million in 2025, then fell by 5.03% to $547.7 million in 2026.
- The last three Total Liabilities figures came in at $547.7 million (Q1 2026), $576.7 million (Q4 2025), and $455.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -61.27 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 85.38 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.71 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 143.08 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 82.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 66.37 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 547.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 547.71 Mn |
| Dec 31, 2025 | 576.73 Mn |
| Sep 30, 2025 | 455.60 Mn |
| Jun 30, 2025 | 332.74 Mn |
| Mar 31, 2025 | 290.46 Mn |
| Dec 31, 2024 | 285.59 Mn |
| Sep 30, 2024 | 311.75 Mn |
| Jun 30, 2024 | 319.24 Mn |
| Mar 31, 2024 | 281.03 Mn |
| Dec 31, 2023 | 274.25 Mn |
| Sep 30, 2023 | 243.20 Mn |
| Jun 30, 2023 | 116.05 Mn |
| Mar 31, 2023 | 74.98 Mn |
| Dec 31, 2022 | 50.29 Mn |
| Sep 30, 2022 | 12.17 Mn |
| Jun 30, 2022 | 52.88 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Dec 31, 2021 | 301.81 Mn |
| Sep 30, 2021 | 10.09 Mn |
| Jun 30, 2021 | 8.90 Mn |